IDYA (IDEAYA Biosciences Inc) Earnings per share for the last four quarters

Public company logo of IDEAYA Biosciences Inc (IDYA)

The current EPS YoY TTM growth trend in the GURU.Markets terminal is illustrated by this chart, where the current level is -144.30. IDEAYA Biosciences (IDYA) price action depends on the outcomes of darovasertib trials and payments from Pfizer and GSK. The company's capital is formed through advances from pharma behemoths for oncology innovations, while the future value of assets is based on the ability to maintain pricing power for synthetic lethality therapies.

IDYA ideayabio.com Earnings per share for the last twelve months (02/11/2024 - 11/16/2026)

IDEAYA Biosciences Inc - analytical breakdowns and key metrics (IDYA)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:IDEAYA Biosciences, Inc. (IDYA)
Signature product of IDEAYA Biosciences, Inc.

This indicator measures the dynamics of net income per share on a rolling annual basis, reflecting the efficiency of monetizing operating results. In the case of IDEAYA Biosciences (IDYA), this metric demonstrates the impact of investments from pharma behemoths on the development of targeted mutation therapies, while the current EPS YoY TTM growth rate allows for an assessment of the risk of false breakouts at historical lows.

Competitor analysis for IDEAYA Biosciences

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX